Farrelly JG - Search Results

1

Preclinical development of new drugs that enhance thyroid hormone metabolism and clearance: inadequacy of using rats as an animal model for predicting human risks in an IND and NDA.

Wu KM, Farrelly JG. Wu KM, et al. Among authors: farrelly jg. Am J Ther. 2006 Mar-Apr;13(2):141-4. doi: 10.1097/01.mjt.0000209673.01885.b0. Am J Ther. 2006. PMID: 16645431 Review.

2

Regulatory toxicology perspectives on the development of botanical drug products in the United States.

Wu KM, Farrelly J, Birnkrant D, Chen S, Dou J, Atrakchi A, Bigger A, Chen C, Chen Z, Freed L, Ghantous H, Goheer A, Hausner E, Osterberg R, Rhee H, Zhang K. Wu KM, et al. Am J Ther. 2004 May-Jun;11(3):213-7. doi: 10.1097/00045391-200405000-00010. Am J Ther. 2004. PMID: 15133537 Review.

3

Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: nonclinical Pharm/Tox analysis and the role of comparative toxicology.

Wu KM, Farrelly JG. Wu KM, et al. Among authors: farrelly jg. Toxicology. 2007 Jul 1;236(1-2):1-6. doi: 10.1016/j.tox.2007.04.005. Epub 2007 Apr 21. Toxicology. 2007. PMID: 17507137

4

Regulatory science: a special update from the United States Food and Drug Administration: Preclinical issues and status of investigation of botanical drug products in the United States.

Wu KM, DeGeorge JG, Atrakchi A, Barry E, Bigger A, Chen C, Du T, Freed L, Geyer H, Goheer A, Jacobs A, Jean D, Rhee H, Osterberg R, Schmidt W, Farrelly JG. Wu KM, et al. Among authors: farrelly jg. Toxicol Lett. 2000 Jan 5;111(3):199-202. doi: 10.1016/s0378-4274(99)00152-6. Toxicol Lett. 2000. PMID: 10643863

5

Complexities of the herbal nomenclature system in traditional Chinese medicine (TCM): lessons learned from the misuse of Aristolochia-related species and the importance of the pharmaceutical name during botanical drug product development.

Wu KM, Farrelly JG, Upton R, Chen J. Wu KM, et al. Among authors: farrelly jg. Phytomedicine. 2007 Apr;14(4):273-9. doi: 10.1016/j.phymed.2006.05.009. Epub 2006 Jul 24. Phytomedicine. 2007. PMID: 16863692

6

Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies.

Black LE, Farrelly JG, Cavagnaro JA, Ahn CH, DeGeorge JJ, Taylor AS, DeFelice AF, Jordan A. Black LE, et al. Among authors: farrelly jg. Antisense Res Dev. 1994 Winter;4(4):299-301. doi: 10.1089/ard.1994.4.299. Antisense Res Dev. 1994. PMID: 7734946

7

Response to Monro and Mehta proposal for use of single-dose toxicology studies to support single-dose studies of new drugs in humans.

Choudary J, Contrera JF, DeFelice A, DeGeorge JJ, Farrelly JG, Fitzgerald G, Goheer MA, Jacobs A, Jordan A, Meyers L, Osterberg R, Resnick C, Sun CJ, Temple RJ. Choudary J, et al. Among authors: farrelly jg. Clin Pharmacol Ther. 1996 Mar;59(3):265-7. doi: 10.1016/S0009-9236(96)80003-8. Clin Pharmacol Ther. 1996. PMID: 8653988 No abstract available.

8

CDER photosafety guidance for industry.

Jacobs AC, Brown PC, Chen C, Ellis A, Farrelly J, Osterberg R. Jacobs AC, et al. Toxicol Pathol. 2004 Jul-Aug;32 Suppl 2:17-8. doi: 10.1080/01926230490463821. Toxicol Pathol. 2004. PMID: 15503660

9

Microsomal metabolism of the Z and E isomers of N-nitroso-N-methyl-N-n-pentylamine.

He C, Farrelly JG. He C, et al. Among authors: farrelly jg. Cancer Lett. 1989 Jun;45(3):189-94. doi: 10.1016/0304-3835(89)90076-1. Cancer Lett. 1989. PMID: 2731161

10

Metabolism of the Z and E isomers of N-nitroso-N-methyl-(2-oxopropyl)amine by rat hepatocytes.

Farrelly JG, Stewart ML, Farnsworth DW, Saavedra JE. Farrelly JG, et al. Cancer Res. 1988 Jun 15;48(12):3347-9. Cancer Res. 1988. PMID: 3370636

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page